CTICのチャート
CTICの企業情報
| symbol | CTIC |
|---|---|
| 会社名 | CTI BioPharma Corp （シ―ティ―アイ・バイオファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 CTIバイオファーマ(CTI BioPharma Corp. )（旧称：Cell Therapeutics Inc.）は癌を治療する毒性の少ない方法の取得・開発・商品化に焦点を当てるバイオ医薬品会社。同社は満たされていない医療ニーズのある血液関連癌向けの治療に力を集中する。同社は主に再発乗算または難治性の積極的な非ホジキンリンパ腫（NHL）のために、欧州連合でPIXUVRI（ピクサントロン）の商品化に従事する他、骨髄線維症の治療用pacritinibの第三相臨床試験を実行する。PIXUVRIは新規アザ・アントラセンジオン誘導体であり、構造的にアントラサイクリン及びアントラセンジオンに関連するが、心毒性作用の同じレベルに関連すると表示されない。 シ―ティ―アイ・バイオファ―マは、米国のバイオ医薬品会社。癌治療法の取得、開発、商業化に従事する。欧州地方で非ホジキンリンパ腫治療の｢PIXUVRI(ピクサントロン)｣を商品化することに焦点を当てる。血液関連癌のスペクトルをカバ―する新たな治療標的を当てるほか癌と共に生きる人々のための治療選択肢の開発も展開する。 CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. The company concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, the company has recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. The company's headquartered in Seattle, Washington. |
| 本社所在地 | 3101 Western Avenue Suite 600 Seattle WA 98121 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 206-282-7100 |
| 設立年月日 | 33482 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 1997年 |
| 従業員数 | 149人 |
| url | www.celltherapeutics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ctic |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -43.17000 |
| 終値（lastsale） | 2.05 |
| 時価総額（marketcap） | 118877294.2 |
| 時価総額 | 時価総額（百万ドル） 118.87730 |
| 売上高 | 売上高（百万ドル） 13.25700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 40.31630 |
| 当期純利益 | 当期純利益（百万ドル） -41.67700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 CTI BioPharma Corp revenues decreased 52% to $11.1M. Net loss applicable to common stockholders decreased 18% to $15.4M. Revenues reflect License and contract revenue decrease of 49% to $11.1M Product sales net decrease from $1M to $0K. Lower net loss reflects Other selling general decrease of 47% to $8.4M (expense) Other non-operating income (expense) increase from $30K (expense) to $4.7M (income). |
CTICのテクニカル分析
CTICのニュース
CTI BioPharma Corp. (NASDAQ: CTIC): Moving Toward A Higher Share Price 2022/06/24 13:00:00 Stocks Register
CTI BioPharma Corp. (NASDAQ:CTIC) shares, rose in value on Thursday, 06/23/22, with the stock price down by -0.17% to the previous day’s close as strong demand from buyers drove the stock to $5.96. Actively observing the price movement in the last trading, the stock closed the session at $5.97, falling within a range of $5.63 … CTI BioPharma Corp. (NASDAQ: CTIC): Moving Toward A Higher Share Price Read More »
CTI BioPharma Corp. (NASDAQ: CTIC) Could Soon Experience A Sharp Increase In Its Share Price. 2022/06/21 19:00:00 Marketing Sentinel
In today’s recent session, 1.47 million shares of the CTI BioPharma Corp. (NASDAQ:CTIC) have been traded, and its beta is 0.86. Most recently the company’s share price was $6.18, and it changed around $0.05 or 0.73% from the last close, which brings the market valuation of the company to $632.00M. CTIC at last check was … CTI BioPharma Corp. (NASDAQ: CTIC) Could Soon Experience A Sharp Increase In Its Share Price. Read More »
Companies - CTI BioPharma Corp. Given Average Recommendation of “Buy” by Analysts 2022/06/20 09:43:10 Business Mag
CTI BioPharma Corp. has been given an average rating of “Buy” by the six ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the…
CTI BioPharma slips after disclosing data for myelofibrosis therapy 2022/06/10 12:31:56 Seeking Alpha
CTI BioPharma (CTIC), a commercial-stage biotech focused on blood-related cancers, dropped ~9% in the pre-market Friday after the company disclosed data for its FDA-approved…
CTI BioPharma rallies 19% to post a 52-week high 2022/06/08 15:31:59 Seeking Alpha
Commercial stage biotech CTI Biopharma (CTIC) has added ~19% in morning hours Wednesday to post the biggest intraday gain since March and reach a 52-week high on above average volume…
CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Wednesday, June 16 2021/06/09 00:00:00 BioSpace
CTI BioPharma Corp. announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:30 p.m. ET.
CTI BioPharma (CTIC) Q1 2021 Earnings Call Transcript 2021/06/02 04:00:26 The Motley Fool
CTIC earnings call for the period ending March 31, 2021.
CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q1 2021 Results - Earnings Call Transcript 2021/06/02 01:16:04 Seeking Alpha
CTI Biopharma net loss widens on R&D expenses, preparations for drug launch 2021/06/01 20:47:55 Seeking Alpha
Must-See Earnings Estimates NASDAQ:RMBL NASDAQ:CALA NASDAQ:CTIC NASDAQ:URGN and #Covid-19 (#Coronavirus) impact 2021/03/21 02:58:00 Stock Market Daily
Earnings, Analyst opinion and estimate and latest Covid-19 (Coronavirus) impact on these hot stocks to invest
CTI BioPharma (NASDAQ:CTIC) Announces Quarterly Earnings Results 2021/03/19 11:28:41 Transcript Daily
CTI BioPharma (NASDAQ:CTIC) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.04), MarketWatch Earnings reports. Shares of NASDAQ CTIC opened at $3.27 on Friday. The firm’s 50-day moving average price is $3.32 and its 200-day moving […]
CTI BioPharma (NASDAQ:CTIC) Releases Earnings Results, Misses Expectations By $0.04 EPS 2021/03/19 04:29:29 Daily Political
CTI BioPharma (NASDAQ:CTIC) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.04), MarketWatch Earnings reports. Shares of NASDAQ CTIC opened at $3.27 on Friday. The stock has a market cap of $246.79 million, a P/E ratio of -4.81 and a […]
CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results 2021/03/17 20:05:00 PR Newswire
SEATTLE, March 17, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2020. "This past quarter, CTI has executed on the critical clinical, regulatory and commercial activities that will allow…
CTI BioPharma to Present at the Cowen 41st Annual Health Care Conference on Thursday, Mar. 4 2021/02/25 12:00:00 PR Newswire
SEATTLE, Feb. 25, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen 41st Annual Health Care Conference at 12:10 p.m. EST. The conference will be held in a virtual meeting format. Presentation details:…